Merck & Co. has picked up options on two Evaxion Biotech vaccine candidates, paying $3.2 million and dangling more than $1 billion in milestones for the chance to pick up preclinical prospects ...

Dimethyl sulfoxide (DMSO) is a compound used in many products, such as makeup, paint removers, cleaners, essential oils, and as a flavoring agent for certain foods. The compound is also naturally ...

Atty. Gloria Camora, the team leader of the COA unit that audited the OVP's confidential funds in 2023, confirmed that the COA issued three audit observation memorandums (AOM) for the OVP's ...

The Commission on Audit (COA) cannot expand its audit powers to include imposing administrative penalties, the Supreme Court (SC) said Wednesday. In Biong vs. COA, the SC sitting En Banc, held that ...

A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, boosting plans to take a second shot at FDA approval. But two more ...

Merck, a leading science and technology company, and Siemens, a leading technology company deepened their mutual cooperation aimed at taking smart manufacturing to the next level. Cedrik Neike, CEO ...

In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative breast cancer (TNBC). Now, the PD-1 inhibitor has gold-standard overall ...

This is the online edition of ESMO in 30 Seconds, a pop-up newsletter from the European Society for Medical Oncology’s annual meeting in Barcelona, Spain. Sign up for the remaining editions ...

After a surprise failure in advanced liver cancer, Merck & Co. and Eisai are hoping new data can make their Keytruda-Lenvima combination a standard of care in intermediate-stage disease.

Get article recommendations from ACS based on references in your Mendeley library. Pair your accounts. Export articles to Mendeley Get article recommendations from ACS based on references in your ...

Summit Therapeutics (NASDAQ:SMMT) shares soar 51% after its investigational bispecific antibody, ivonescimab, reduced the risk of disease progression or death by 49% compared to Merck’s (NYSE ...

But that doesn’t necessarily threaten the market dominance of Keytruda, a top Merck executive said — and some analysts agree. “I see these results as important, but preliminary,” Merck ...